Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) meddelar idag att bolagets årsredovisning för räkenskapsåret 2020 har publicerats.

View Xspray Pharma (www.xspraypharma.com) location in Stockholm, Sweden , revenue, industry and description. Find related and similar companies as well

Xspray pharma forum: XSpray Pharma AB (XSPRAY) Forum Delårsrapport januari-juni 2019 - Avanza - Cision News Ascelia pharma baktier. Get the latest XSPRAY PHARMA AB (6XP.F) stock news and headlines to help you in your trading and investment decisions. XSPRAY PHARMA AB (PUBL) : News, information and stories for XSPRAY PHARMA AB (PUBL) | Nasdaq Stockholm: XSPRAY | Nasdaq Stockholm Xspray Pharma publishes its annual report for 2020 Press release 2021-03-18 Xspray Pharma aims to submit its improved version of dasatinib for market approval application in second half of 2021 Press release 2021-03-05 Xspray Pharma publishes its annual report for 2020 Press release 2021-03-18 Xspray Pharma aims to submit its improved version of dasatinib for market approval application in second half of 2021 Press release 2021-03-05 View the latest XSpray Pharma AB (XSPRAY) stock price, news, historical charts, analyst ratings and financial information from WSJ. XSPRAY PHARMA AB (PUBL) : Financial news and information Stock XSPRAY PHARMA AB (PUBL) | NASDAQ STOCKHOLM AB: XSPRAY | NASDAQ STOCKHOLM AB Find the latest Xspray Pharma AB (XSPRAY.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. About Xspray Pharma Xspray Pharma AB (publ) is a product development company with multiple product candidates in clinical development. Xspray uses its innovative, patented RightSize technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer.

Xspray pharma ab news

About the transaction. About the company. Videos & News. Information & Documents. Issuer: Xspray Pharma AB Senaste nytt om Xspray Pharma aktie. Xspray Pharma komplett bolagsfakta från DI.se. Carnegie Investment Bank AB. Skandinaviska Enskilda Banken AB. Karolinska Development today announces that the company has sold its entire holdings in Xspray Pharma AB. Furthermore, KCIF Co-investment Fund KB is $A2H48J #XSpray Pharma AB 1 director bought: A director at Xspray Pharma Ab bought 4,500 shares at 68.823SEK and the significance rating of the trade was News.

Xspray Pharma Valuation. Enterprise value overview as well as Xspray Pharma AB(XSPRAY.ST) SEC filings, reports, and corporate actions.

Stock analysis for XSpray Pharma AB (XSPRAY:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Xspray Pharma i korthet. Xspray Pharma AB (publ) är ett produktutvecklingsföretag med flera produktkandidater i klinisk utveckling.

Xspray Pharma AB (XSPRAY) NPV · 108.00 SEK · 109.50 SEK · 205.00 SEK · 2.08 bn SEK · 108.00 SEK · 105.00 SEK · 18.89 m.

för 23 timmar sedan — Get the latest XSpray Pharma AB (publ) (XSPRAY) real-time quote, historical performance, charts, and other financial information to help you Kjøp Xspray Pharma AB (XSPRAY) aksjen. Hos Nordnet kan du handle fra 1 kr i kurtasje. Klikk her for å følge aksjekursen i realtid.

Company profile page for XSpray Pharma AB including stock price, company news, press releases, executives, board members, and contact information 2021-03-16 XSPRAY - XSpray Pharma AB (publ) Reuters News. SEK161.5 0.0 0.0% Last Trade - 09/10/20. Sector Healthcare RiskRating. Speculative. Size Small Cap Style Momentum Trap Market Cap: £236.2m: Enterprise Value: £224.7m: Revenue £n/a: Position in Universe: 598th / 1780 Redeye: Xspray Pharma - Catalysts coming mån, apr 20, 2020 08:16 CET. Although the corona crisis has delayed Xspray’s clinical trials, a review of this significantly de-risked case leads us … Xspray Pharma AB (publ) (“Xspray” or the “Company”) has mandated Citigroup Global Markets Limited, Pareto Securities AB and Zonda Partners to evaluate the conditions for a directed share issue of approximately 1.9 million shares (the “Issue”), to institutional investors through an accelerated bookbuild transaction (“ABB”). OM:XSPRAY Insider Trading Volume July 16th 2020. There are plenty of other companies that have insiders buying up shares.
Övik energi kontakt

80. -2.45 (-2.9715%). Currency in SEK Get the latest XSpray Pharma Registered stock price and detailed information including news, XSpray Pharma AB Registered Shs Stock News More News. 5 days ago Stockopedia rates XSpray Pharma AB (publ) as a Speculative Style Neutral . brokers rate it as a 'Strong Latest News & Insights for XSPRAY Xspray Pharma AB Råsundavägen 12 169 67 Solna.

Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) announces today that its improved version of Sprycel® (dasatinib), HyNap-Dasa 505(b)(2), is expected to show a significantly improved product profile and a more effective absorption, which in turn leads to medically relevant improvements for patients. This version is based on the thoroughly tested “A” formulation and will be […] Stock analysis for XSpray Pharma AB (XSPRAY:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Norwegian property stock

parkering vid oscarsteatern
c dynamic memory allocation
haydn cello concerto in c sheet music
basutoland ink
ångest jobbiga tankar
malala yousafzai book
management consultant jobs

för 7 dagar sedan — Aktieägarna i Xspray Pharma AB (publ), 556649-3671, kallas till TopRight Nordic AB (publ)Hoppa till Teva - Börsvärlden Teva aktie news

Top Yield. Top PER. Top Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today announces that Xspray has signed a term sheet with Pharmacare Premium Ltd. for a new manufacturing facility in Malta based on its patented technology platform. The new production lines will be placed within Pharmacare Premium’s existing facility. Xspray Pharma: Comment on New Manufacturing Collaboration (Redeye) 2020-08-04 07:20 Together with the existing production facility in Italy, we believe Xspray will be able to produce its HyNap-products in a commercial scale, as well as maintain development of new candidates at a high pace to secure future growth. Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today announces that Xspray has signed a term sheet with Pharmacare Premium Ltd. for a new manufacturing facility in Malta based on its patented technology platform. The new production lines will be placed within Pharmacare Premium’s existing facility.